Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Rocío Torrecilla-Olavarrieta, José Pérez-Revuelta, Edgar García-Spínola, Ángela López Martín, José María Mongil-SanJuan, Carmen Rodríguez-Gómez, José María Villagrán-Moreno & Francisco González-Saiz. (2021) Satisfaction with antipsychotics as a medication: the role of therapeutic alliance and patient-perceived participation in decision making in patients with schizophrenia spectrum disorder. International Journal of Psychiatry in Clinical Practice 25:3, pages 268-276.
Read now
Read now
Rahul Dhanda, Della Varghese, Vijay R Nadipelli, Maurizio Fava, Namita Joshi, Caitlyn T Solem, James A Graham, Susan M Learned & Christian Heidbreder. (2019) Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study. Patient Preference and Adherence 13, pages 1037-1050.
Read now
Read now
Leslie Citrome, Joseph P McEvoy, Mark S Todtenkopf, David McDonnell & Peter J Weiden. (2019) A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatric Disease and Treatment 15, pages 2559-2569.
Read now
Read now
Francesco Pietrini, Umberto Albert, Andrea Ballerini, Paola Calò, Giuseppe Maina, Federica Pinna, Marco Vaggi, Ileana Boggian, Maria Fontana, Cesare Moro & Bernardo Carpiniello. (2019) The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia. Neuropsychiatric Disease and Treatment 15, pages 1045-1060.
Read now
Read now
Ludger Hargarter, Marjolein Lahaye, Pierre Cherubin, Martin Lambert, Marnina Swarz, Gali Joldygulov, Flavio Vischia, Veronica Chomskaya, Vasilis P. Bozikas, Eva-Maria Tsapakis & Andreas Schreiner. (2018) Treatment response and tolerability with once-monthly paliperidone palmitate initiated shortly after hospital admission in patients with schizophrenia. The World Journal of Biological Psychiatry 19:sup3, pages S147-S157.
Read now
Read now
Articles from other publishers (13)
Katarzyna Szyszko vel Chorazy, Simone Agnes Efkemann, Udo Schneider & Georg Juckel. (2022) Multi-dimensional recording of long-term treatment of patients with schizophrenic disorders compared to patients with major depression measured with the ASSESS battery. Heliyon 8:12, pages e11924.
Crossref
Crossref
A. S. Piatoikina, T. V. Zhilyaeva & G. E. Mazo. (2022) Cognitive impairments in schizophrenia and their impact on oxidative stress. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY 56:3, pages 66-79.
Crossref
Crossref
Manuel Rojas, Maite Barrios, Juana Gómez-Benito, Nadezhda Mikheenkova & Sergey Mosolov. (2021) Functioning Problems in Persons with Schizophrenia in the Russian Context. International Journal of Environmental Research and Public Health 18:19, pages 10276.
Crossref
Crossref
Chi-Un Pae, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar & Prakash S. Masand. (2021) Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study. Clinical Psychopharmacology and Neuroscience 19:2, pages 233-242.
Crossref
Crossref
Blanca Fernández-Abascal, Maria Recio-Barbero, Margarita Sáenz-Herrero & Rafael Segarra. (2021) Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report. Therapeutic Advances in Psychopharmacology 11, pages 204512532199127.
Crossref
Crossref
S.K. Zyryanov, I.N. Dyakov, A.A. Juperin, D.A. Egorova & E.S. Mosolova. (2020) The pharmacoeconomic efficacy of lurasidone in the treatment of schizophrenia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 120:6, pages 82.
Crossref
Crossref
N. Maslenikov, E. Tsukarzi & S. Mosolov. (2019) P.838 Repetitive transcranial magnetic stimulation for depression in schizophrenia: Focus on cognitive functions. European Neuropsychopharmacology 29, pages S557-S558.
Crossref
Crossref
Natalia Petros, Andrea Mechelli, Paolo Fusar-Poli, Sandra Vieira, Emma Rowland & Philip McGuire. (2019) Towards a framework for good outcome in people at clinical high risk for psychosis: A Delphi consensus study. Schizophrenia Research 208, pages 209-216.
Crossref
Crossref
S. N. Mosolov, A. V. Malyutin & A. A. Pikalov. (2019) Effect of Lurasidone on symptoms of schizophrenia in five-factor dimensional model: pooled analysis of two short-term, randomized, double-blind, placebo-controlled studies in patients from Russia and Ukraine. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119:12, pages 29.
Crossref
Crossref
I. N. Dyakov & S. K. Zyryanov. (2019) Clinical and economic efficiency of treatment with cariprazine in schizophrenia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119:7, pages 69.
Crossref
Crossref
Mariia Dorofeikova, Nikolay Neznanov & Nataliia Petrova. (2018) Cognitive deficit in patients with paranoid schizophrenia: Its clinical and laboratory correlates. Psychiatry Research 262, pages 542-548.
Crossref
Crossref
John J. Isitt, Vijay R. Nadipelli, Alex Kouassi, Maurizio Fava & Christian Heidbreder. (2016) Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. Schizophrenia Research 174:1-3, pages 126-131.
Crossref
Crossref
In-Jo Park, Dong Chung Jung, Samuel Suk-Hyun Hwang, Hee Yeon Jung, Jin-Sang Yoon, Chul-Eung Kim, Yong Min Ahn & Yong Sik Kim. (2016) The longitudinal trends in the relationship between drug-induced extrapyramidal symptoms and personal and social performance in a population of the patients with schizophrenia: A latent growth model. Psychiatry Research 238, pages 33-39.
Crossref
Crossref